论文部分内容阅读
人红细胞生成素重组体(r- HuEPO)于1984年生产成功,次年发表了有关论文。其过程为:制取与再生障碍性贫血者尿中提取的红细胞生成素的N末端氨基酸序列对应的合成DNA探针,再由基因库中取出与DNA探针相对应的基因,然后在中国仓鼠卵巢细胞(CHO)上进行纯株培养。由此成功地生产出rEPO(分子量35000Da)。rEPO为一种糖蛋白,其中糖占40%。因为由大肠杆菌制取的rEPO不含糖,无红细胞生成素活性,所以须采用CHO的制取方法。
The recombinant human erythropoietin (r-HuEPO) was successfully produced in 1984 and published the following year. The process is as follows: a synthetic DNA probe corresponding to the N-terminal amino acid sequence of erythropoietin extracted from the urine of an aplastic anemia patient is prepared, and then the gene corresponding to the DNA probe is taken out from the gene bank, Pure culture was performed on ovarian cells (CHO). As a result, rEPO (molecular weight 35,000 Da) was successfully produced. rEPO is a glycoprotein in which 40% of the sugar is consumed. Because rEPO prepared from E. coli does not contain sugar, no erythropoietin activity, so the preparation of CHO to be used.